In this first part of a video series, Susan Cantrell, CEO of AMCP, discussed root causes of high drug prices, its impact on underserved communities and Medicare price negotiation, emphasizing AMCP's actions and the role of decreasing drug prices for equity.
AMCP CEO Susan Cantrell spoke with Managed Healthcare Executive about the challenges of pinpointing specific causes for high drug prices.
Cantrell emphasized the crucial role of innovation in driving prescription drug costs, sharing the exciting advancements in therapies for long-standing health issues. However, she did caution against some policy solutions that might intervene in any innovations.
Additionally, she stressed the importance of payment models, supporting the Medicaid Value-Based Payments for Patients (MVP) Act to enhance Medicaid patients' access to high-cost therapies.
At AMCP, her team focuses on advocating for the appropriate use of medications and promoting generics and biosimilars to address cost concerns.
When asked about the significant increase in existing prescription drug costs, Cantrell acknowledged the steady rise but stressed the complexity of data and sources in providing precise figures.
Lastly, Cantrell highlighted the need for a multi-stakeholder approach involving patients, health plans, benefit managers, employers, manufacturers and healthcare delivery systems to find effective solutions that balance access, affordability and innovation.
Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators
July 9th 2020In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More
HHS Needs More Rebate Information To Negotiate Medicare Drug Prices, Say USC Experts
February 19th 2024The Health and Human Services department could wind up overpaying (or possibly underpaying) for the drugs for which it is negotiating a “maximum fair price” for Medicare under the Inflation Reduction Act, argue experts at the USC Schaeffer Center for Health Policy and Economics. A fuller picture of rebates and net prices could help that from happening, they say.
Read More
ICER Updates its Assessment Framework to Include New Measures of Value
September 25th 2023ICER adds a more formal process to evaluate the diversity of clinical trials and an assessment of a product’s impact on patient and caregiver productivity. ICER also plans to evaluate how newer methods — which would consider the change of a drug’s price over time and disease severity — can be applied to its value assessment.
Read More